Sharyn Shepherd
Family · Corvallis, ORNPI 1629591987
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,561 of the $3,102 with a category attached, or 82.6%. It is spread thinly across 41 manufacturers, the largest accounting for just 10.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,500, more than ten times the $121 reported in 2021. Among family clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 102 payments — averaging $30.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$315
- Novartis$276
- Sanofi$187
- Bristol Myers Squibb$182
- Blueprint Medicines Corporation$157
- Astellas Pharma US Inc$132
- plus $2K from 35 others
What the payments were for
- Food & beverage$2,56183%
- Education$54117%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 11 | $315 |
| Novartis | 11 | $276 |
| Sanofi | 4 | $187 |
| Bristol Myers Squibb | 8 | $182 |
| Blueprint Medicines Corporation | 2 | $157 |
| Astellas Pharma US Inc | 3 | $132 |
| Daiichi Sankyo Inc. | 5 | $113 |
| Gilead | 2 | $112 |
| AstraZeneca | 2 | $111 |
| Genentech USA, Inc. | 2 | $111 |
| AbbVie | 4 | $104 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Myriad Genetic Laboratories, Inc. | 1 | $94 |
| Exelixis Inc. | 4 | $77 |
| Incyte Corporation | 1 | $74 |
| E.r. Squibb & Sons, L.L.C. | 3 | $62 |
| Merck | 2 | $60 |
| Beone Medicines USA, Inc. | 3 | $60 |
| EMD Serono, Inc. | 2 | $59 |
| Stemline Therapeutics Inc. | 3 | $57 |
| Pfizer | 2 | $56 |
| Bayer | 3 | $55 |
| Geron Corporation | 2 | $53 |
| Caris MPI, Inc. | 2 | $46 |
| Ipsen Biopharmaceuticals, Inc | 2 | $43 |
| Mirati Therapeutics, Inc. | 1 | $40 |
| Coherus Oncology, Inc. | 1 | $40 |
| AVEO Pharmaceuticals, Inc. | 2 | $38 |
| Genmab U.S., Inc. | 1 | $31 |
| Sumitomo Pharma America, Inc. | 1 | $29 |
| Spectrum Pharmaceuticals Inc. | 1 | $26 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Pharmacosmos Therapeutics Inc. | 1 | $22 |
| Morphosys, US Inc. | 1 | $22 |
| Adaptive Biotechnologies Corporation | 1 | $21 |
| GSK | 1 | $20 |
| Beigene USA, Inc. | 1 | $20 |
| Legend Biotech USA Inc. | 1 | $20 |
| Novo Nordisk | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Clovis Oncology, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AYVAKIT$125
How this compares
$3,102 in reported general payments places this provider in the 95th percentile of 1,130 family providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 19 | $15,595 |
| Letrozole | 99 | $3,538 |
| Anastrozole | 84 | $1,903 |
| Tamoxifen Citrate | 40 | $1,305 |
| Fentanyl | 12 | $1,275 |
| Oxycodone Hcl | 39 | $1,041 |
| Hydroxyurea | 31 | $529 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 40 | $457 |
| Gabapentin | 19 | $348 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 11 | $255 |
| Ondansetron OdtOndansetron | 11 | $242 |
| Pregabalin | 18 | $224 |
| Omeprazole | 11 | $192 |
| Lorazepam | 22 | $88 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $56 | $15,59519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,130 family providers in Oregon.
Other family in Corvallis
- Heather HermanCorvallis$34K
- Rachel PangilinanPortland$103K
- Jodeanna SweeneyCentral Point$45K
- Lani DoserPortland$45K
- David ArnopoleMedford$38K
- Amy BartramOregon City$33K
- Leah GaedekePortland$26K
- Bobbi Lee RothTualatin$23K
- Susan ToftePortland$21K
- Leah WessenbergPortland$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.